TELA Bio shares offer ‘attractive upside for 2024,’ says Lake Street

Lake Street analyst Frank Takkinen thinks TELA Bio enters 2024 with “all five of its growth factors on solid footing,” noting that the company is on track to exit 2023 with 75-80 reps, a “robust product portfolio,” sufficient GPO access and “strong clinical data.” The firm, which also thinks TELA will improve its execution compared to Street expectations throughout 2024, sees the shares offering “attractive upside for 2024” and reiterates a Buy rating and $14 price target for the shares.